1. Amsterdam Investigator–initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design 
Pier Woudstra, MD, Maik J. Grundeken, MD, Robin P. Kraak, MD, Mariëlla E.C.J. Hassell, MD, E. Karin Arkenbout, PhD, MD, Jan Baan, PhD, MD, Marije M. Vis, PhD, MD, Karel T. Koch, MD, PhD, Jan G.P. Tijssen, PhD, Jan J. Piek, MD, PhD, Robbert J. de Winter, MD, PhD, José P.S. Henriques, MD, PhD, Joanna J. Wykrzykowska, MD, PhD 
American Heart Journal 
Volume 167, Issue 2, Pages (February 2014)
DOI: /j.ahj
Copyright © 2014 Mosby, Inc. Terms and Conditions

2. Figure 1
Enrollment scheme. In the case of emergency PCI, the patient provides oral consent before randomization and written consent for the follow-up trial procedures is obtained after the procedure. Full written informed consent is mandatory before the procedure in the case of elective PCI. If patients are not enrolled in the study, they are anonymized registered into a screening log. ID, identification; IWRS, Interactive Web Response System; QOL, quality of life.
American Heart Journal  , DOI: ( /j.ahj )
Copyright © 2014 Mosby, Inc. Terms and Conditions

3. Figure 2
Follow-up scheme. *The XIENCE family is composed of the XIENCE PRIME and XIENCE Xpedition stents. †The Quality of Life questionnaires taken are the EQ-5D and SAQ. If patients are enrolled in the study, follow-up is obtained up to 5 years after the index procedure by telephone contact or a scheduled outpatient clinic visit. Both at 1 year and at 2 years of follow-up, the Quality of Life questionnaires are taken by all participating subjects.
American Heart Journal  , DOI: ( /j.ahj )
Copyright © 2014 Mosby, Inc. Terms and Conditions